EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?
Eur J Health Econ
.
2018 Sep;19(7):905-907.
doi: 10.1007/s10198-017-0944-0.
Authors
F Antoñanzas
1
,
C A Juárez-Castelló
2
,
R Rodríguez-Ibeas
2
Affiliations
1
Department of Economics, University of La Rioja, 26004, Logroño, Spain. fernando.antonanzas@unirioja.es.
2
Department of Economics, University of La Rioja, 26004, Logroño, Spain.
PMID:
29188395
DOI:
10.1007/s10198-017-0944-0
No abstract available
Publication types
Editorial
MeSH terms
Drug Approval / economics
Drug Approval / methods*
Drug Costs
Drug Industry
European Union
Humans
Reimbursement, Incentive* / economics
Reimbursement, Incentive* / organization & administration